GlassScriptPhysician profile
Roger V Torres
NPI 1326091117
$27,515.93
in general payments reported to CMS, 2019-2025
64 companies · $3,771 in 2025
The $3,771 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,594 · 2020: $3,756 · 2021: $4,052 · 2022: $3,950 · 2023: $4,174 · 2024: $4,218 · 2025: $3,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,061.30 |
| Education | $102.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,413.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $2,291.19 | 2019-2025 | Repatha, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,971.50 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,895.00 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $1,683.84 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,500.59 | 2019-2025 | |
| Novo Nordisk INC | $1,336.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $995.53 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $911.54 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $882.26 | 2019-2024 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $835.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $696.34 | 2019-2025 | Eliquis, Camzyos |
| Aimmune Therapeutics, INC. | $672.37 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $577.53 | 2019-2025 | Linzess |
| Merck Sharp & Dohme LLC | $536.71 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $502.42 | 2019-2024 | Hyqvia, Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $493.33 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $491.30 | 2019-2024 | Livalo, Seglentis |
| Allergan, INC. | $456.36 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.64 | 2019-2024 | Trulance, Xifaxan |
| Amarin Pharma, INC. | $437.35 | 2020-2022 | |
| Esperion Therapeutics, INC. | $326.94 | 2020-2024 | Nexletol |
| Nestle Healthcare Nutrition INC. | $251.59 | 2021-2023 | |
| Mylan Specialty L.P. | $227.28 | 2019-2024 | Yupelri |
| Radius Health, INC. | $223.49 | 2019-2025 | Tymlos |
| Eisai INC. | $220.75 | 2020-2022 | |
| Exact Sciences Corporation | $218.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $208.85 | 2019 | |
| Idorsia Pharmaceuticals US INC | $199.71 | 2022-2025 | Quviviq, Quviviq |
| Scilex Pharmaceuticals INC. | $181.86 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $175.29 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $174.80 | 2024-2025 | Voquezna |
| Almatica Pharma LLC | $170.37 | 2021-2023 | Loreev Xr, Gralise |
| Ardelyx, INC. | $156.62 | 2023-2024 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $126.82 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.98 | 2025 | Caplyta |
| Dexcom, INC. | $100.77 | 2021-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $93.20 | 2022-2023 | Krystexxa |
| Genentech USA, INC. | $84.45 | 2020-2021 | |
| Medicure Pharma INC. | $83.16 | 2020 | |
| Ge Healthcare | $83.05 | 2022-2024 | |
| Insmed, INC. | $82.49 | 2025 | Arikayce, Brinsupri |
| Seqirus USA INC | $82.08 | 2022-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Boston Scientific Corporation | $81.13 | 2025 | Watchman Access System |
| Biohaven Pharmaceuticals, INC. | $80.27 | 2021 | |
| Lundbeck LLC | $62.37 | 2024-2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $60.70 | 2022-2023 | Unithroid |
| Otsuka America Pharmaceutical, INC. | $60.53 | 2022-2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $58.34 | 2023 | Inpefa |
| Optinose US, INC. | $51.68 | 2020-2021 | |
| Corcept Therapeutics | $49.79 | 2023 | Korlym |
| Baxter Healthcare | $44.04 | 2023 | Hillrom - Life 2000 Ventilation System |
| Biohaven Pharmaceutical Holding Company LTD. | $42.10 | 2022 | |
| Medtronic Vascular, INC. | $42.05 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $36.19 | 2025 | Acthar |
| Avanir Pharmaceuticals, INC. | $34.28 | 2019 | |
| Medtronic, INC. | $33.65 | 2021-2024 | Minimed 780g |
| Sanofi Pasteur INC. | $31.52 | 2019-2020 | |
| Amphastar Pharmaceuticals, INC. | $31.49 | 2024 | Baqsimi |
| Opko Pharmaceuticals, LLC | $23.96 | 2022 | |
| Nevro Corp. | $22.55 | 2022 | |
| Tonix Medicines, INC. | $20.91 | 2025 | Tonmya |
| Ibsa Pharma INC. | $18.17 | 2022 | |
| Qol Medical, LLC | $16.22 | 2023 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.